rs12160838
Variant names: 
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_145912.8(NFAM1):c.663+301C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.167 in 151,998 control chromosomes in the GnomAD database, including 2,265 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
 Genomes: 𝑓 0.17   (  2265   hom.,  cov: 32) 
Consequence
 NFAM1
NM_145912.8 intron
NM_145912.8 intron
Scores
 2
Clinical Significance
 Not reported in ClinVar 
Conservation
 PhyloP100:  -2.02  
Publications
4 publications found 
Genes affected
 NFAM1  (HGNC:29872):  (NFAT activating protein with ITAM motif 1) The protein encoded by this gene is a type I membrane receptor that activates cytokine gene promoters such as the IL-13 and TNF-alpha promoters. The encoded protein contains an immunoreceptor tyrosine-based activation motif (ITAM) and is thought to regulate the signaling and development of B-cells. [provided by RefSeq, Jul 2008] 
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.99). 
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.208  is higher than 0.05. 
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt | 
|---|---|---|---|---|---|---|---|---|
| NFAM1 | NM_145912.8  | c.663+301C>T | intron_variant | Intron 4 of 5 | ENST00000329021.10 | NP_666017.1 | ||
| NFAM1 | NM_001371362.1  | c.507+301C>T | intron_variant | Intron 6 of 7 | NP_001358291.1 | |||
| NFAM1 | NM_001318323.3  | c.550+301C>T | intron_variant | Intron 3 of 4 | NP_001305252.1 | 
Ensembl
Frequencies
GnomAD3 genomes   AF:  0.167  AC: 25312AN: 151880Hom.:  2264  Cov.: 32 show subpopulations 
GnomAD3 genomes 
 AF: 
AC: 
25312
AN: 
151880
Hom.: 
Cov.: 
32
Gnomad AFR 
 AF: 
Gnomad AMI 
 AF: 
Gnomad AMR 
 AF: 
Gnomad ASJ 
 AF: 
Gnomad EAS 
 AF: 
Gnomad SAS 
 AF: 
Gnomad FIN 
 AF: 
Gnomad MID 
 AF: 
Gnomad NFE 
 AF: 
Gnomad OTH 
 AF: 
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome   AF:  0.167  AC: 25329AN: 151998Hom.:  2265  Cov.: 32 AF XY:  0.165  AC XY: 12271AN XY: 74284 show subpopulations 
GnomAD4 genome 
 AF: 
AC: 
25329
AN: 
151998
Hom.: 
Cov.: 
32
 AF XY: 
AC XY: 
12271
AN XY: 
74284
show subpopulations 
African (AFR) 
 AF: 
AC: 
8777
AN: 
41462
American (AMR) 
 AF: 
AC: 
2546
AN: 
15272
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
323
AN: 
3466
East Asian (EAS) 
 AF: 
AC: 
8
AN: 
5170
South Asian (SAS) 
 AF: 
AC: 
433
AN: 
4818
European-Finnish (FIN) 
 AF: 
AC: 
2019
AN: 
10546
Middle Eastern (MID) 
 AF: 
AC: 
24
AN: 
294
European-Non Finnish (NFE) 
 AF: 
AC: 
10637
AN: 
67944
Other (OTH) 
 AF: 
AC: 
330
AN: 
2116
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.498 
Heterozygous variant carriers
 0 
 1048 
 2096 
 3143 
 4191 
 5239 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
 0 
 258 
 516 
 774 
 1032 
 1290 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
Alfa 
 AF: 
Hom.: 
Bravo 
 AF: 
Asia WGS 
 AF: 
AC: 
189
AN: 
3478
ClinVar
Not reported inComputational scores
Source: 
Name
Calibrated prediction
Score
Prediction
 BayesDel_noAF 
 Benign 
 DANN 
 Benign 
 PhyloP100 
Splicing
Name
Calibrated prediction
Score
Prediction
 SpliceAI score (max) 
Details are displayed if max score is > 0.2
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at 
Publications
 You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.